Interest of Azithromycin With or Without Hydroxychloroquine for the Treatment of COVID-19 Pneumonia : a Retrospective Observational Study
Overview
- Phase
- Not Applicable
- Intervention
- favorable outcome
- Conditions
- COVID
- Sponsor
- Centre d'Investigation Clinique et Technologique 805
- Enrollment
- 132
- Locations
- 1
- Primary Endpoint
- Favorable outcome
- Status
- Completed
- Last Updated
- 5 years ago
Overview
Brief Summary
During COVID-19 epidemic, hydroxychloroquine was proposed and authorized as a possible key agent in the treatment of COVID-19 hospitalized pneumonia, including in France. Gautret et al. proposed the combination regimen with azithromycin. However only one study reported the interest of azithromycin alone.
Retrospective study reporting the impact of the anti-infective agents used during the pandemic in a tertiary care hospital, using azithromycin with or without hydroxychloroquine.
Investigators
Eligibility Criteria
Inclusion Criteria
- •aged over 18 years old
- •hospitalized for a COVID-19 pneumonia documented by PCR or lung tomodensitometry,
- •admitted outside an intensive care unit, in a medicine ward
Exclusion Criteria
- •patient opposed to data collected, or who could not consent because of a serious presentation of the pneumonia
Arms & Interventions
Azithromycin or non-azithromycin group
Patient who received during admission for a severe COVID-19 pneumonia, azithromycin +/-hydroxychloroquine or no azithromycin.
Intervention: favorable outcome
Outcomes
Primary Outcomes
Favorable outcome
Time Frame: Assessed within 7 days after admission
After being admitted, patient was monitored whether he does not required to be transferred in ICU or died because of a severe COVID-19 pneumonia within 7 days. The outcome was purely clinical. If patient was discharged at home after admission and/or was transferred into a rehabilitation center he was considered as a favorable outcome independently of any biological marker.
Secondary Outcomes
- Interest of anti-infective agents(From date of inclusion until the date of first documented progression to ICU or date of death from any cause, whichever came first, assessed up to 2 months)
- Risk factors 1(Assessed at day 1)
- Risk factors 2(Assessed at day 1)